Pacira BioSciences
PCRX
196 hedge funds and large institutions have $1.97B invested in Pacira BioSciences in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 84 increasing their positions, 54 reducing their positions, and 29 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
56% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 54
25% more call options, than puts
Call options by funds: $23.2M | Put options by funds: $18.5M
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
2% more funds holding
Funds holding: 192 → 196 (+4)
5% more capital invested
Capital invested by funds: $1.87B → $1.97B (+$93M)
6.75% less ownership
Funds ownership: 109.53% → 102.79% (-6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$32.2M |
| 2 |
Millennium Management
New York
|
+$27.5M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$19M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.9M |
| 5 |
CHP
Castle Hook Partners
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$44.3M |
| 2 |
PC
PointState Capital
New York
|
-$29.4M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$28M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$23M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$21M |
PCRX Hedge Fund Activity: Q2 2017 in Review
196 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2017, worth a combined $1.97B — up 5% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PCRX positions and 29 closed out — a net gain of 4 holders — while 84 added to existing stakes and 54 trimmed.
The largest buyer was HealthCor Management, adding an estimated $32.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $44.3M sold.
- 196 institutional investors held Pacira BioSciences (PCRX) as of Q2 2017, up from 192 in Q1 2017.
- Funds reported $1.97B of Pacira BioSciences stock for Q2 2017, up 5% quarter-over-quarter.
- 33 funds opened new Pacira BioSciences positions in Q2 2017 and 29 closed out, a net change of +4 holders.
- The largest Pacira BioSciences buyer in Q2 2017 was HealthCor Management, an estimated $32.2M added.
- The largest Pacira BioSciences seller in Q2 2017 was Consonance Capital Management, an estimated $44.3M sold.
Based on aggregated 13F filings for Q2 2017.